First Patient Enrolled in BrainStorm's Phase II ALS Trial
News Jun 10, 2014
BrainStorm Cell Therapeutics has announced that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital (MGH) in Boston.
BrainStorm’s Phase II trial is a randomized, double-blind, placebo controlled multi-center study designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors ("MSC-NTF" or NurOwn™) in 48 ALS patients.
The trial is also being conducted at the University of Massachusetts Memorial (UMass) Hospital in Worcester, MA and the Mayo Clinic in Rochester, Minnesota.
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE
Stem-Cell Exosome Treatment Repairs Brain Damage Following StrokeNews
A team of researchers have developed a new treatment for stroke that reduces brain damage and accelerates the brain’s natural healing tendencies in animal models.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018